Literature DB >> 16732184

Dendritic cells activated by lipopolysaccharide after dexamethasone treatment induce donor-specific allograft hyporesponsiveness.

Peter M Emmer1, Johan van der Vlag, Gosse J Adema, Luuk B Hilbrands.   

Abstract

BACKGROUND: Immature dendritic cells (imDC) can prolong allograft survival in murine transplantation models. Recent data indicate that semi-mature or alternatively activated DC (aaDC) may be even more tolerogenic.
METHODS: We compared the phenotype and regulatory capacity of: a) imDC, cultured in the presence of dexamethasone (DEX), b) mature DC (matDC), activated with LPS, and c) aaDC, activated with LPS after pretreatment with DEX.
RESULTS: As compared to imDC, aaDCs displayed a slight upregulation of CD40 while expression levels of MHC-II and CD86 remained low. The production of proinflammatory cytokines, in particular IL-12, by aaDC was much lower than by matDC while both produced similar amounts of the regulatory cytokine IL-10 leading to an increased IL-10/IL-12 ratio for aaDC. After infusion of donor type aaDCs, responder cells isolated from the recipient mice showed donor-specific hyporesponsiveness to restimulation by matDC. Infusion of matDC was immunogenic, while imDC induced partial hyporesponsiveness. Importantly, pretreatment with donor type aaDC (but not imDC) resulted in prolonged survival of a completely MHC-mismatched heart allograft.
CONCLUSIONS: Alternatively activated DC are more efficacious than the classical imDC in the regulation of the alloimmune response, which may be related to a distinct cytokine profile characterized by an increased IL-10/IL12 ratio.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16732184     DOI: 10.1097/01.tp.0000208801.51222.bd

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  30 in total

1.  Endogenous dendritic cells mediate the effects of intravenously injected therapeutic immunosuppressive dendritic cells in transplantation.

Authors:  Sherrie J Divito; Zhiliang Wang; William J Shufesky; Quan Liu; Olga A Tkacheva; Angela Montecalvo; Geza Erdos; Adriana T Larregina; Adrian E Morelli
Journal:  Blood       Date:  2010-06-24       Impact factor: 22.113

2.  Dendritic cells treated with crude Plasmodium berghei extracts acquire immune-modulatory properties and suppress the development of autoimmune neuroinflammation.

Authors:  Rodolfo Thomé; Luidy K Issayama; Thiago Alves da Costa; Rosária D Gangi; Isadora T Ferreira; Catarina Rapôso; Stefanie C P Lopes; Maria Alice da Cruz Höfling; Fábio T M Costa; Liana Verinaud
Journal:  Immunology       Date:  2014-10       Impact factor: 7.397

3.  Biomaterial adjuvant effect is attenuated by anti-inflammatory drug delivery or material selection.

Authors:  Lori W Norton; Jaehyung Park; Julia E Babensee
Journal:  J Control Release       Date:  2010-06-02       Impact factor: 9.776

Review 4.  Tolerogenic dendritic cells in organ transplantation.

Authors:  Jordi Ochando; Farideh Ordikhani; Stefan Jordan; Peter Boros; Angus W Thomson
Journal:  Transpl Int       Date:  2019-10-29       Impact factor: 3.782

5.  Donor-derived, tolerogenic dendritic cells suppress immune rejection in the indirect allosensitization-dominant setting of corneal transplantation.

Authors:  Takaaki Hattori; Daniel R Saban; Parisa Emami-Naeini; Sunil K Chauhan; Toshinari Funaki; Hiroki Ueno; Reza Dana
Journal:  J Leukoc Biol       Date:  2012-01-30       Impact factor: 4.962

6.  Dendritic cell therapies in transplantation revisited: deletion of recipient DCs deters the effect of therapeutic DCs.

Authors:  Z Wang; S J Divito; W J Shufesky; T Sumpter; H Wang; O A Tkacheva; W Wang; C Liu; A T Larregina; A E Morelli
Journal:  Am J Transplant       Date:  2012-04-14       Impact factor: 8.086

Review 7.  Regulatory myeloid cells in transplantation.

Authors:  Brian R Rosborough; Dàlia Raïch-Regué; Heth R Turnquist; Angus W Thomson
Journal:  Transplantation       Date:  2014-02-27       Impact factor: 4.939

8.  Tolerogenic Donor-Derived Dendritic Cells Risk Sensitization In Vivo owing to Processing and Presentation by Recipient APCs.

Authors:  Lesley A Smyth; Kulachelvy Ratnasothy; Aurelie Moreau; Sally Alcock; Pervinder Sagoo; Lucy Meader; Yakup Tanriver; Matthew Buckland; Robert Lechler; Giovanna Lombardi
Journal:  J Immunol       Date:  2013-03-27       Impact factor: 5.422

9.  Dexamethasone transforms lipopolysaccharide-stimulated human blood myeloid dendritic cells into myeloid dendritic cells that prime interleukin-10 production in T cells.

Authors:  Brenda M Bosma; Herold J Metselaar; Nicole M A Nagtzaam; Roel de Haan; Shanta Mancham; Luc J W van der Laan; Ernst J Kuipers; Jaap Kwekkeboom
Journal:  Immunology       Date:  2008-02-27       Impact factor: 7.397

10.  LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells.

Authors:  Amy E Anderson; David J Swan; Bethan L Sayers; Rachel A Harry; Angela M Patterson; Alexei von Delwig; John H Robinson; John D Isaacs; Catharien M U Hilkens
Journal:  J Leukoc Biol       Date:  2008-11-06       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.